<p>香港，2026 年 5 月 4 日 -（ACN Newswire）-2026 年 5 月 4 日早上 6:18，隨着最後生產工序的成功完成，中國旭陽集團在運城生產基地的 5 萬噸/年己內酰胺轉化為六亞甲基二胺（HMDA）工廠全面整合，實現了一次性成功投產並生產出合格產品。通過直接從己內酰胺生產 HMDA，中國旭陽打破了長期以來對己二腈技術的外國壟斷（己二腈是 HMDA 的關鍵原料，是尼龍 66 的中間體，被視為尼龍產業鏈的 “咽喉”）。這一 “瓶頸” 技術的突破為中國旭陽在高端新材料領域的戰略佈局奠定了基礎，逐步構建百萬噸規模的 “尼龍 6 + 尼龍 66 + 特種尼龍” 產業集羣，建立國家級尼龍新材料基地。</p>
<p>行業背景與當前發展</p>
<p>HMDA 是支持尼龍新材料產業升級的關鍵原料。其生產技術的創新與突破對中國化工行業的發展具有重要意義。目前，行業依賴於基於丁二烯的工藝生產己二腈，再轉化為 HMDA。儘管這一路線已經成熟，但存在顯著缺陷：一方面，由於丁二烯原料價格波動，生產成本依然較高；另一方面，工藝複雜，技術壁壘極高，關鍵專利長期被海外企業壟斷。</p>
<p>在此背景下，中國旭陽集團開創了獨立的研發路徑，開發出一種新技術和工藝，直接從己內酰胺生產 HMDA。這一創新打破了行業壟斷，克服了關鍵技術壁壘，為 HMDA 的生產開闢了新路徑。</p>
<p>中國旭陽的研發歷程與創新成就</p>
<p>作為全球最大的獨立焦炭生產商和供應商，以及差異化煤化工運營的全球領導者，中國旭陽集團緊密對接國家戰略需求，準確把握產業轉型趨勢。早在 2011 年，公司就預見到己內酰胺產業的潛力，擴大規模的同時建立研發團隊，開展對己內酰胺及下游產業新工藝和技術的獨立研究。</p>
<p>在十多年的時間裏，中國旭陽的研發團隊進行了超過一千次實驗室規模的實驗，穩步推進到中試規模建設和穩定運行，最終實現全面工業化。在從實驗室到中試規模、工藝開發和工業化的過程中，團隊攻克了百餘個研究課題，獲得了數十項擁有完全自主知識產權的核心專利，成功開發出直接從己內酰胺生產 HMDA 的創新工藝路線。</p>
<p>鑑於這一成就的顛覆性、開創性和戰略價值，山東省已將中國旭陽集團的項目列為省級重點工程。</p>
<p>中國旭陽的核心產業優勢與競爭力</p>
<p>HMDA 項目的投產凸顯了中國旭陽在產業協同和研發創新方面的優勢，顯著提升了其在尼龍新材料領域的核心競爭力，鞏固了其在化工行業的領導地位。</p>
<ol>
<li>穩定高效的產業協同</li>
</ol>
<p>HMDA 工廠的穩定運行和全面生產將與集團現有的 81 萬噸/年己內酰胺產業鏈及運城工業園區的上游生產線（包括己二酸、環己酮和硝酸）形成協同。這種整合實現了資源互補、技術升級、產能擴張和效率最大化。</p>
<p>中國旭陽集團在芳烴產業鏈上具有堅實基礎，從苯到己內酰胺再到 HMDA，進一步向下游高端產業（如聚合物顆粒、纖維紡織、織造、注塑、改性和聚氨酯）延伸。這加速了覆蓋 “上游原材料 - 中游單體 - 下游產品” 的完整尼龍 6 + 尼龍 66 + 特種尼龍產業鏈的建設。</p>
<ol>
<li>持續的研發與創新能力</li>
</ol>
<p>與傳統工藝相比，己內酰胺轉化為 HMDA 技術具有明顯優勢：工藝流程簡化、投資成本降低、安全性更高、原料轉化率提高。</p>
<p>該工藝和催化劑均受中國旭陽的自主知識產權保護，突破了國內外在聚酰胺原料方面的技術壁壘，填補了中國的關鍵空白。</p>
<ol>
<li>持續的工藝優化與成本降低</li>
</ol>
<p>中國旭陽的己內酰胺轉化為 HMDA 技術相比於丁二烯路線實現了顯著降低的單位生產成本。未來研發與生產的整合將進一步降低運營成本。</p>
<p>作為全球第二大己內酰胺生產商，中國旭陽的規模優勢、產業鏈整合和全面的配套基礎設施使其 HMDA 產品具有高度的成本競爭力。</p>
<p>未來規劃與發展戰略</p>
<p>圍繞己內酰胺產業鏈，中國旭陽集團已經開發並儲備了多項技術和產品，包括 HMDA 和彈性尼龍。隨着核心技術的持續穩定與升級，中國旭陽將擴大規模，為中國的尼龍 66 及相關產業注入新的動力。</p>
<p>展望未來，中國旭陽集團將繼續致力於以創新驅動的發展和服務導向的增長，深化其垂直整合模式，戰略性地培育高端化學品和新材料，並系統性地加強其新材料組合。公司致力於幫助中國進一步克服化學和新材料技術壁壘，構建現代化、自主可控的工業體系，實現尼龍 66 等關鍵材料的國產替代，為國家貢獻中國旭陽的力量。</p>
<p>版權 © 2026 ACN Newswire。保留所有權利。</p>

中國旭陽集團

<p>中國旭陽集團已成功啓動其新建的 5 萬噸/年己二胺（HMDA）工廠，打破了對腈綸技術的外資壟斷。這一創新使得可以直接從己內酰胺生產 HMDA，提升了中國的尼龍產業。該項目被山東省認定為重點工程，展示了旭陽的研發能力和產業協同，顯著降低了生產成本並提高了效率。公司旨在擴大其尼龍相關產品的供應，並加強在高端化學品市場的地位</p>

<p>HONG KONG, May 4, 2026 - (ACN Newswire) - At 6:18 a.m. on May 4, 2026, with the successful completion of the final production process, China Risun Group's 50,000-ton/year caprolactam-to-hexamethylenediamine (HMDA) plant at the Yuncheng Production Base was fully integrated, achieving a one-time successful start-up and producing qualified products. By directly producing HMDA from caprolactam, China Risun has broken the long-standing foreign monopoly on adiponitrile technology (adiponitrile is the key raw material for HMDA, the intermediate for nylon 66, and is regarded as the 'throat' of the nylon industry chain). This breakthrough in 'chokepoint' technology lays the foundation for China Risun's strategic deployment in high-end new materials, gradually building a million-ton-scale 'nylon 6 + nylon 66 + specialty nylon' industrial cluster, and establishing a national-level nylon new materials base.</p>
<div class="lb-trans"><p>香港，2026 年 5 月 4 日 -（ACN Newswire）-2026 年 5 月 4 日早上 6:18，隨着最後生產工序的成功完成，中國旭陽集團在運城生產基地的 5 萬噸/年己內酰胺轉化為六亞甲基二胺（HMDA）工廠全面整合，實現了一次性成功投產並生產出合格產品。通過直接從己內酰胺生產 HMDA，中國旭陽打破了長期以來對己二腈技術的外國壟斷（己二腈是 HMDA 的關鍵原料，是尼龍 66 的中間體，被視為尼龍產業鏈的 “咽喉”）。這一 “瓶頸” 技術的突破為中國旭陽在高端新材料領域的戰略佈局奠定了基礎，逐步構建百萬噸規模的 “尼龍 6 + 尼龍 66 + 特種尼龍” 產業集羣，建立國家級尼龍新材料基地。</p>
</div><p>Industry Background and Current Development</p>
<div class="lb-trans"><p>行業背景與當前發展</p>
</div><p>HMDA is a critical raw material supporting the upgrading of the nylon new materials industry. Innovation and breakthroughs in its production technology are of great significance to the development of China's chemical industry. Currently, the industry relies on the butadiene-based process to produce adiponitrile and then HMDA. Although mature, this route has notable shortcomings: on one hand, production costs remain high due to fluctuations in butadiene feedstock prices; on the other hand, the process is complex, with extremely high technical barriers, and key patents have long been monopolized by overseas enterprises.</p>
<div class="lb-trans"><p>HMDA 是支持尼龍新材料產業升級的關鍵原料。其生產技術的創新與突破對中國化工行業的發展具有重要意義。目前，行業依賴於基於丁二烯的工藝生產己二腈，再轉化為 HMDA。儘管這一路線已經成熟，但存在顯著缺陷：一方面，由於丁二烯原料價格波動，生產成本依然較高；另一方面，工藝複雜，技術壁壘極高，關鍵專利長期被海外企業壟斷。</p>
</div><p>Against this backdrop, China Risun Group pioneered an independent R&amp;D path, developing a new technology and process to directly produce HMDA from caprolactam. This innovation breaks industry monopolies, overcomes critical technical barriers, and opens up a new route for HMDA production.</p>
<div class="lb-trans"><p>在此背景下，中國旭陽集團開創了獨立的研發路徑，開發出一種新技術和工藝，直接從己內酰胺生產 HMDA。這一創新打破了行業壟斷，克服了關鍵技術壁壘，為 HMDA 的生產開闢了新路徑。</p>
</div><p>China Risun's R&amp;D Journey and Innovation Achievements</p>
<div class="lb-trans"><p>中國旭陽的研發歷程與創新成就</p>
</div><p>As the world's largest independent coke producer and supplier, and a global leader in differentiated coal chemical operations, China Risun Group has closely aligned with national strategic needs and accurately grasped industrial transformation trends. As early as 2011, the company foresaw the potential of the caprolactam industry, expanding its scale while establishing R&amp;D teams to carry out independent research on new processes and technologies for caprolactam and downstream industries.</p>
<div class="lb-trans"><p>作為全球最大的獨立焦炭生產商和供應商，以及差異化煤化工運營的全球領導者，中國旭陽集團緊密對接國家戰略需求，準確把握產業轉型趨勢。早在 2011 年，公司就預見到己內酰胺產業的潛力，擴大規模的同時建立研發團隊，開展對己內酰胺及下游產業新工藝和技術的獨立研究。</p>
</div><p>Over more than a decade, China Risun's R&amp;D team conducted over a thousand laboratory-scale experiments, steadily advancing to pilot-scale construction and stable operation, and ultimately achieving full industrial implementation. Throughout the journey from lab-scale to pilot-scale, process development, and industrialization, the team tackled over a hundred research topics, secured dozens of core patents with fully independent intellectual property rights, and successfully developed the innovative process route of directly producing HMDA from caprolactam.</p>
<div class="lb-trans"><p>在十多年的時間裏，中國旭陽的研發團隊進行了超過一千次實驗室規模的實驗，穩步推進到中試規模建設和穩定運行，最終實現全面工業化。在從實驗室到中試規模、工藝開發和工業化的過程中，團隊攻克了百餘個研究課題，獲得了數十項擁有完全自主知識產權的核心專利，成功開發出直接從己內酰胺生產 HMDA 的創新工藝路線。</p>
</div><p>Given the disruptive, pioneering, and strategic value of this achievement, Shandong Province has designated China Risun Group's project as a provincial key engineering initiative.</p>
<div class="lb-trans"><p>鑑於這一成就的顛覆性、開創性和戰略價值，山東省已將中國旭陽集團的項目列為省級重點工程。</p>
</div><p>China Risun's Core Industrial Advantages and Competitiveness</p>
<div class="lb-trans"><p>中國旭陽的核心產業優勢與競爭力</p>
</div><p>The commissioning of the HMDA project highlights China Risun's strengths in industrial synergy and R&amp;D innovation, significantly enhancing its core competitiveness in nylon new materials and consolidating its leadership position in the chemical industry.</p>
<div class="lb-trans"><p>HMDA 項目的投產凸顯了中國旭陽在產業協同和研發創新方面的優勢，顯著提升了其在尼龍新材料領域的核心競爭力，鞏固了其在化工行業的領導地位。</p>
</div><p>1. Stable and Efficient Industrial Synergy</p>
<div class="lb-trans"><ol>
<li>穩定高效的產業協同</li>
</ol>
</div><p>The stable operation and full-scale production of the HMDA plant will synergize with the Group's existing 810,000-ton/year caprolactam industry chain and upstream production lines at Yuncheng Industrial Park, including adipic acid, cyclohexanone, and nitric acid. This integration enables resource complementarity, technological upgrading, capacity expansion, and maximized efficiency.</p>
<div class="lb-trans"><p>HMDA 工廠的穩定運行和全面生產將與集團現有的 81 萬噸/年己內酰胺產業鏈及運城工業園區的上游生產線（包括己二酸、環己酮和硝酸）形成協同。這種整合實現了資源互補、技術升級、產能擴張和效率最大化。</p>
</div><p>China Risun Group has a strong foundation in the aromatics industry chain, extending from benzene to caprolactam to HMDA, and further downstream into high-end industries such as polymer chips, fiber spinning, weaving, injection molding, modification, and polyurethane. This accelerates the construction of a full nylon 6 + nylon 66 + specialty nylon industry chain covering 'upstream raw materials - midstream monomers - downstream products.'</p>
<div class="lb-trans"><p>中國旭陽集團在芳烴產業鏈上具有堅實基礎，從苯到己內酰胺再到 HMDA，進一步向下游高端產業（如聚合物顆粒、纖維紡織、織造、注塑、改性和聚氨酯）延伸。這加速了覆蓋 “上游原材料 - 中游單體 - 下游產品” 的完整尼龍 6 + 尼龍 66 + 特種尼龍產業鏈的建設。</p>
</div><p>2. Continuous R&amp;D and Innovation Capacity</p>
<div class="lb-trans"><ol>
<li>持續的研發與創新能力</li>
</ol>
</div><p>Compared with traditional processes, the caprolactam-to-HMDA technology offers clear advantages: simplified process flow, lower investment costs, higher safety, and improved raw material conversion rates.</p>
<div class="lb-trans"><p>與傳統工藝相比，己內酰胺轉化為 HMDA 技術具有明顯優勢：工藝流程簡化、投資成本降低、安全性更高、原料轉化率提高。</p>
</div><p>Both the process and catalyst are protected by China Risun's independent intellectual property rights, breaking through domestic and international technical barriers in polyamide raw materials and filling a critical gap in China.</p>
<div class="lb-trans"><p>該工藝和催化劑均受中國旭陽的自主知識產權保護，突破了國內外在聚酰胺原料方面的技術壁壘，填補了中國的關鍵空白。</p>
</div><p>3. Ongoing Process Optimization and Cost Reduction</p>
<div class="lb-trans"><ol>
<li>持續的工藝優化與成本降低</li>
</ol>
</div><p>China Risun's caprolactam-to-HMDA technology achieves significantly lower unit production costs compared with the butadiene route. Future integration of R&amp;D and production will further reduce operating costs.</p>
<div class="lb-trans"><p>中國旭陽的己內酰胺轉化為 HMDA 技術相比於丁二烯路線實現了顯著降低的單位生產成本。未來研發與生產的整合將進一步降低運營成本。</p>
</div><p>As the world's second-largest caprolactam producer, China Risun's scale advantages, industry chain integration, and comprehensive supporting infrastructure make its HMDA products highly cost-competitive.</p>
<div class="lb-trans"><p>作為全球第二大己內酰胺生產商，中國旭陽的規模優勢、產業鏈整合和全面的配套基礎設施使其 HMDA 產品具有高度的成本競爭力。</p>
</div><p>Future Planning and Development Strategy</p>
<div class="lb-trans"><p>未來規劃與發展戰略</p>
</div><p>Around the caprolactam industry chain, China Risun Group has already developed and reserved multiple technologies and products, including HMDA and elastic nylon. With the continuous stabilization and upgrading of its core technologies, China Risun will expand its scale and inject new momentum into China's nylon 66 and related industries.</p>
<div class="lb-trans"><p>圍繞己內酰胺產業鏈，中國旭陽集團已經開發並儲備了多項技術和產品，包括 HMDA 和彈性尼龍。隨着核心技術的持續穩定與升級，中國旭陽將擴大規模，為中國的尼龍 66 及相關產業注入新的動力。</p>
</div><p>Looking ahead, China Risun Group will remain committed to innovation-driven development and service-oriented growth, deepening its vertically integrated model, strategically cultivating high-end chemicals and new materials, and systematically strengthening its new materials portfolio. The company is dedicated to helping China further overcome chemical and new materials technology barriers, building a modernized, autonomous, and controllable industrial system, and achieving domestic substitution of key materials such as nylon 66-contributing China Risun's strength to the nation.</p>
<div class="lb-trans"><p>展望未來，中國旭陽集團將繼續致力於以創新驅動的發展和服務導向的增長，深化其垂直整合模式，戰略性地培育高端化學品和新材料，並系統性地加強其新材料組合。公司致力於幫助中國進一步克服化學和新材料技術壁壘，構建現代化、自主可控的工業體系，實現尼龍 66 等關鍵材料的國產替代，為國家貢獻中國旭陽的力量。</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版權 © 2026 ACN Newswire。保留所有權利。</p>
</div>

突破 “卡脖子” 技術：中國旭陽集團的己二胺工廠已開始投產